Brian T. Tsuji
About
Brian T. Tsuji is a scholar working on Molecular Medicine, Pharmacology and Infectious Diseases.
According to data from OpenAlex, Brian T. Tsuji has authored 112 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Molecular Medicine, 72 papers in Pharmacology and 40 papers in Infectious Diseases. Recurrent topics in Brian T. Tsuji's work include Antibiotic Resistance in Bacteria (76 papers), Antibiotics Pharmacokinetics and Efficacy (72 papers) and Antimicrobial Resistance in Staphylococcus (35 papers). Brian T. Tsuji is often cited by papers focused on Antibiotic Resistance in Bacteria (76 papers), Antibiotics Pharmacokinetics and Efficacy (72 papers) and Antimicrobial Resistance in Staphylococcus (35 papers). Brian T. Tsuji collaborates with scholars based in United States, Australia and South Korea. Brian T. Tsuji's co-authors include Alan Forrest, Roger L. Nation, Jürgen B. Bulitta, Jian Li, Michael J. Rybak, Phillip J. Bergen, Neang S. Ly, Keith S. Kaye, Cornelia B. Landersdorfer and Justin R. Lenhard and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Scientific Reports.
In The Last Decade
Brian T. Tsuji
110 papers receiving 5.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Brian T. Tsuji United States | 41 | 3.5k | 2.8k | 1.6k | 1.1k | 1.0k | 112 | 5.2k | ||
| Jürgen B. Bulitta United States | 45 | 3.4k 1.0× | 3.4k 1.2× | 1.8k 1.1× | 862 0.8× | 935 0.9× | 187 | 6.2k | ||
| Philippe Lagacé‐Wiens Canada | 38 | 2.9k 0.8× | 1.8k 0.7× | 1.7k 1.1× | 1.3k 1.1× | 794 0.8× | 126 | 5.3k | ||
| Andrew Walkty Canada | 34 | 2.8k 0.8× | 1.9k 0.7× | 1.6k 1.0× | 1.0k 0.9× | 736 0.7× | 126 | 4.7k | ||
| Alexandre Prehn Zavascki Brazil | 35 | 3.5k 1.0× | 2.4k 0.9× | 1.5k 1.0× | 589 0.5× | 822 0.8× | 116 | 4.9k | ||
| Ursula Theuretzbacher Austria | 31 | 1.9k 0.6× | 2.1k 0.8× | 1.6k 1.0× | 1.3k 1.1× | 958 0.9× | 61 | 5.4k | ||
| Michael N. Dudley United States | 41 | 3.0k 0.8× | 3.1k 1.1× | 1.9k 1.2× | 1.3k 1.1× | 737 0.7× | 135 | 5.6k | ||
| Jason M. Pogue United States | 42 | 3.8k 1.1× | 2.9k 1.0× | 1.9k 1.2× | 1.5k 1.3× | 652 0.6× | 155 | 6.4k | ||
| Craig R. Rayner United States | 31 | 2.1k 0.6× | 1.9k 0.7× | 1.6k 1.0× | 1.4k 1.2× | 732 0.7× | 82 | 4.7k | ||
| Sheryl Zelenitsky Canada | 31 | 2.0k 0.6× | 2.1k 0.8× | 1.3k 0.8× | 1.0k 0.9× | 563 0.5× | 80 | 4.3k | ||
| Carl Urban United States | 32 | 3.0k 0.9× | 1.4k 0.5× | 1.2k 0.8× | 827 0.7× | 650 0.6× | 94 | 4.2k |
Countries citing papers authored by Brian T. Tsuji
Since
Specialization
Citations
This map shows the geographic impact of Brian T. Tsuji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian T. Tsuji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian T. Tsuji more than expected).
Fields of papers citing papers by Brian T. Tsuji
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Brian T. Tsuji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian T. Tsuji. The network helps show where Brian T. Tsuji may publish in the future.
Co-authorship network of co-authors of Brian T. Tsuji
This figure shows the co-authorship network connecting the top 25 collaborators of Brian T. Tsuji. A scholar is included among the top collaborators of Brian T. Tsuji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian T. Tsuji. Brian T. Tsuji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Smith, Nicholas M., Raymond Cha, Yinzhi Lang, et al.. (2024). Next generation antibiotic combinations to combat pan-drug resistant Klebsiella pneumoniae. Scientific Reports. 14(1). 3148–3148.
2.
Zhou, Jieqiang, Yuli Qian, Yinzhi Lang, et al.. (2024). Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug degradation. Antimicrobial Agents and Chemotherapy. 68(3). e0139923–e0139923.
3.
Liu, Yang, Patricia N. Holden, Barry N. Kreiswirth, et al.. (2024). Maximally precise combinations to overcome metallo-β-lactamase-producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 68(10). e0077024–e0077024.
4.
Smith, Nicholas M., et al.. (2024). PBP-3 directed therapy in VIM-producing Pseudomonas aeruginosa creates bacterial transformers, persisters in disguise. International Journal of Antimicrobial Agents. 64(3). 107260–107260.
5.
Smith, Nicholas M., et al.. (2023). 2547. Targeting penicillin-binding protein 2 (PBP2) to treat metallo-beta-lactamase (MBL)-producing Klebsiella pneumoniae: Mecillinam as an American Ninja Warrior. Open Forum Infectious Diseases. 10(Supplement_2).
6.
Bulitta, Jürgen B., Phillip J. Bergen, Yinzhi Lang, et al.. (2023). Distinguishing Inducible and Non-Inducible Resistance to Colistin in Pseudomonas aeruginosa by Quantitative and Systems Pharmacology Modeling at Low and Standard Inocula. Journal of Pharmaceutical Sciences. 113(1). 202–213.
7.
Smith, Nicholas M., Liang Chen, Vidmantas Petraitis, et al.. (2022). Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity. Antimicrobial Agents and Chemotherapy. 66(9). e0052722–e0052722.
8.
Li, Chen, Jason M. Pogue, Varun Sharma, et al.. (2020). Correction: ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. JMIR mhealth and uhealth. 8(12). e26593–e26593.
9.
Li, Chen, Jason M. Pogue, Varun Sharma, et al.. (2020). ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. JMIR mhealth and uhealth. 8(12). e20525–e20525.
10.
Jiao, Yuanyuan, Bartolomé Moyá, Alexandre Prehn Zavascki, et al.. (2019). Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Antimicrobial Agents and Chemotherapy. 63(7).
11.
Tsuji, Brian T., Jason M. Pogue, Alexandre Prehn Zavascki, et al.. (2019). International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 39(1). 10–39.
12.
Lenhard, Justin R., Zackery P. Bulman, Brian T. Tsuji, & Keith S. Kaye. (2019). Shifting Gears: The Future of Polymyxin Antibiotics. Antibiotics. 8(2). 42–42.
13.
Bergen, Phillip J., et al.. (2019). Rational Combinations of Polymyxins with Other Antibiotics. Advances in experimental medicine and biology. 1145. 251–288.
14.
Maifiah, Mohd Hafidz Mahamad, Darren J. Creek, Roger L. Nation, et al.. (2017). Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii. Scientific Reports. 7(1). 45527–45527.
15.
Tängdén, Thomas, Véronique Martin, Tim Felton, et al.. (2017). The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Medicine. 43(7). 1021–1032.
16.
Rao, Gauri G., Neang S. Ly, Alan Forrest, et al.. (2016). Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. International Journal of Antimicrobial Agents. 48(3). 331–336.
17.
Bergen, Phillip J., Jürgen B. Bulitta, Alan Forrest, et al.. (2010). Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model. Antimicrobial Agents and Chemotherapy. 54(9). 3783–3789.
18.
Tsuji, Brian T., et al.. (2009). A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(1). 80–94.
19.
Bulitta, Jürgen B., Alan Forrest, George Sakoulas, et al.. (2009). Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia. Antimicrobial Agents and Chemotherapy. 53(9). 3894–3901.
20.
Tsuji, Brian T. & Michael J. Rybak. (2005). Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagnostic Microbiology and Infectious Disease. 54(1). 73–77.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jürgen B. Bulitta Breakdown of academic impact, for papers by Philippe Lagacé‐Wiens Breakdown of academic impact, for papers by Andrew Walkty Breakdown of academic impact, for papers by Alexandre Prehn Zavascki Breakdown of academic impact, for papers by Ursula Theuretzbacher Breakdown of academic impact, for papers by Michael N. Dudley Breakdown of academic impact, for papers by Jason M. Pogue Breakdown of academic impact, for papers by Craig R. Rayner Breakdown of academic impact, for papers by Sheryl Zelenitsky Breakdown of academic impact, for papers by Carl Urban